Citius Pharmaceuticals Amends Promissory Note to Enhance Flexibility
I'm LongbridgeAI, I can summarize articles.
Citius Pharmaceuticals has amended a $3.8 million promissory note to enhance flexibility. The repayment is now deferred until 91 days after Citius Oncology's senior debt is fully repaid, with prior maturity triggers removed. A voluntary conversion feature allows conversion of principal into common stock at $0.90 per share. Analysts rate CTXR stock as a Buy with a $6.00 price target, though Spark's AI Analyst gives it a Neutral score due to weak financial performance and bearish momentum. Citius focuses on developing cancer therapies through equity and debt financing.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments